Novel therapy for idiopathic pulmonary fibrosis-How to evaluate the efficacy?

Respiratory Medicine CME

Volumn 1, Issue 2, 2008, Pages 75-81

  Azuma, Arata ^a   Usuki, Jiro ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

Exercise endurance test; Idiopathic pulmonary fibrosis; Interferon ; N acetylcysteine; Pirfenidone; Progression free survival interval

Indexed keywords

ACETYLCYSTEINE; AZATHIOPRINE; BOSENTAN; ENDOTOXIN; GAMMA INTERFERON; IMMUNOSUPPRESSIVE AGENT; PIRFENIDONE; PLACEBO; POLYMIXICIN; PREDNISOLONE; STEROID;

ANOREXIA; ARTICLE; CLINICAL TRIAL; DIAGNOSTIC IMAGING; DIAGNOSTIC PROCEDURE; DISEASE EXACERBATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG WITHDRAWAL; ENDURANCE; FIBROSING ALVEOLITIS; HUMAN; LOW DRUG DOSE; LUNG CANCER; LUNG FUNCTION TEST; NAUSEA; PATHOPHYSIOLOGY; PHOTOSENSITIVITY; PRIORITY JOURNAL; PROGNOSIS; STOMACH DISCOMFORT; TREADMILL EXERCISE; WALKING;

EID: 49349092317     PISSN: 17550017     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmedc.2008.06.001     Document Type: Article

References (30)

1. The Japanese Respiratory Society, Committee for Formulation of Diffuse Pulmonary Disease Diagnosis and Treatment Guidelines: Idiopathic Interstitial pneumonias-guide to diagnosis and treatment. Tokyo, Nankodo, 2004.
2. American thoracic society: idiopathic pulmonary fibrosis: diagnosis and treatment. International Consensus Statement. ATS and ERS. Am J Respir Crit Care Med 161 (2000) 646-664
3. Katzenstein A.L., and Fiorelli R.F. Nonspecific interstitial pneumonia/fibrosis. Histologic features and clinical significance. Am J Surg Pathol 18 2 (1994) 136-147
4. Ziesche R., Hofbauer E., Wittmann K., Petkov V., and Block L.H. A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. N Engl J Med 341 17 (1999) 1264-1269
5. Raghu G., Brown K.K., Bradford W.Z., Starko K., Noble P.W., Schwartz D.A., et al. Idiopathic Pulmonary Fibrosis Study Group. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med 350 2 (2004) 125-133
6. Kalra S., Utz J.P., and Ryu J.H. Mayo Clinic Interstitial Lung Diseases Group. Interferon gamma-1b therapy for advanced idiopathic pulmonary fibrosis. Mayo Clin Proc 78 9 (2003) 1082-1087
7. Selman M. A dark side of interferon-in the treatment of idiopathic pulmonary fibrosis?. Am J Respir Crit Care Med 167 (2003) 945-946
8. Honore I., Nunes H., Groussard O., Kambouchner M., Chambellan A., Aubier M., et al. Acute respiratory failure after interferon-therapy of end-stage pulmonary fibrosis. Am J Respir Crit Care Med 167 (2003) 953-957
9. Bajwa E.K., Ayas N.T., Schulzer M., Mak E., Ryu J.H., and Malhotra A. Interferon-g1b therapy in idiopathic pulmonary fibrosis. Chest 128 (2005) 203-206
10. 〈www.investor.intermune.com/〉, Company Announces Plans for Pivotal Phase III Trial of Actimmune in IPF. July 29, 2003.
11. http://www.bloomberg.com/apps/news?pid=20601202&sid= ahj9UbSLuSSA&refer=healthcare
12. Meyer A., Buhl R., and Magnussen H. The effect of oral N-acetylcysteine on lung glutathione levels in idiopathic pulmonary fibrosis. Eur Respir J 7 (1994) 431-436
13. Behr J., Maier K., Degenkolb B., Krombach F., and Vogelmeier C. Antioxidative and clinical effects of high-dose N-acetylcysteine in fibrosing alveolitis. Adjunctive therapy to maintenance immunosuppression. Am J Respir Crit Care Med 156 6 (1997) 1897-1901
14. Maurits Demedts M.D., Juergen Behr M.D., Roland B., et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 353 21 (2005) 2229-2242
15. Ishii Y, Kitamura S, Sugiyama Y. NAC adsorption therapy for idiopathic interstitial pneumonias: analysis of effective examples from open clinical trials. Health Science Research Specified Diseases Research Project, Diffuse Pulmonary Disease Study Group, 2000 Research report of Ministry of Health, Welfare and Labor of Japan.
16. Raghu G., Johnson W.C., Lockhart D., and Mageto Y. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label Phase II study. Am J Respir Crit Care Med 159 (1999) 1061-1069
17. Azuma A., Nukiwa T., Tsuboi E., et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 171 (2005) 1040-1047
18. Azuma A., Hagiwara K., and Kudoh S. Letter; Basis of acute exacerbation of idiopathic pulmonary fibrosis in Japanese. Am J Respir Crit Care Med xx(x) 177 (2008) 1397-1398
19. Ogura T, Ebina M, Taniguchi H, Azuma A, Suga M, Taguchi Y, Pirfenidone Clinical Study Group. A Phase III, double-blind, placebo-controlled clinical trial of pirfenidone in patients with idiopathic pulmonary fibrosis in Japan. Mini-symposium (interstitial lung disease). International conference of American thoracic society (ATS2008. in Toronto, Canada), 2008, p. 5.20.
20. Collard H.R., Moore B.B., Flaherty K.R., Brown K.K., Kaner R.J., King Jr. T.E., et al. Idiopathic pulmonary fibrosis clinical research network investigators. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 176 7 (2007) 636-643
21. Kondoh Y., Taniguchi H., Kawabata Y., et al. Acute exacerbation in idiopathic pulmonary fibrosis. Analysis of clinical and pathologic findings in three cases. Chest 103 (1993) 1808-1812
22. Seo Y., Abe S., Kurahara M., Okada D., Saito Y., Usuki J., et al. Beneficial effect of polymyxin B-immobilized fiber column (PMX) hemoperfusion treatment on acute exacerbation of idiopathic pulmonary fibrosis. Inter Med 45 18 (2006) 1033-1038
23. Kojika M., Sato N., Yaegashi Y., Suzuki Y., Suzuki K., Nakae H., et al. Endotoxin adsorption therapy for septic shock using polymyxin B-immobilized fibers (PMX): evaluation by high-sensitivity endotoxin assay and measurement of the cytokine production capacity. Ther Apher Dial 10 1 (2006) 12-18
24. Latsi P.I., du Bois R.M., Nicholson A.G., Colby T.V., Bisirtzoglou D., Nikolakopoulou A., et al. Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. Am J Respir Crit Care Med 168 (2003) 531-537
25. Lettieri C.J., Nathan S.D., Barnett S.D., Ahmad S., and Shorr A.F. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest 129 (2006) 746-752
26. Flaherty K.R., Andrei A.C., Murray S., Fraley C., Colby T.V., Travis W.D., et al. Idiopathic pulmonary fibrosis: prognostic value of changes in physiology and six-minute-walk test. Am J Respir Crit Care Med 174 7 (2006) 803-809
27. Lama V.N., Flaherty K.R., Toews G.B., Colby T.V., Travis W.D., Long Q.I., et al. Prognostic Value of Desaturation during a 6-Minute Walk Test in Idiopathic Interstitial Pneumonia. Am J Respir Crit Care Med 168 (2003) 1084-1090
28. Hallstrand T.S., Boitano L.J., Johnson W.C., Spada C.A., Hayes J.G., and Raghu G. The timed walk test as a measure of severity and survival in idiopathic pulmonary fiborsis. Eur Respir J 25 (2005) 96-103
29. Kubo H., Nakayama K., Yanai M., Suzuki T., Yamaya M., Watanabe M., et al. Anticoagulant therapy for idiopathic pulmonary fibrosis. Chest 128 3 (2005) 1475-1482
30. Gahl W.A., Brantly M., Troendle J., et al. Effect of pirfenidone on the pulmonary fibrosis of Hermansky-Padluck syndrome. Mol Genet Metab 76 (2002) 234-242